



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/913,538	08/15/2001	Fuminori Sato		9756

513 7590 11/12/2003

WENDEROTH, LIND & PONACK, L.L.P.
2033 K STREET N. W.
SUITE 800
WASHINGTON, DC 20006-1021

EXAMINER

LUKTON, DAVID

ART UNIT	PAPER NUMBER
----------	--------------

1653

DATE MAILED: 11/12/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/913,538

Applicant(s)

SATO ET AL.

Examiner

David Lukton

Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 August 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7,9 and 10 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 1-3,6 and 7 is/are allowed.
- 6) ☒ Claim(s) 4,9 and 10 is/are rejected.
- 7) ☒ Claim(s) 5 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ 6) ☐ Other: _____

Pursuant to preliminary amendment, claims 1 and 3 have been amended.

Claims 1-7, 9-10 are pending.

✱

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 10 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claim 10 recites the term "pharmaceutical". This term implies an assertion of therapeutic efficacy, which is not in evidence. The specification (page 2) asserts that any or all of the following diseases can be successfully treated: pulmonary emphysema, adult respiratory distress syndrome (ARDS), idiopathic interstitial pneumonia, cystic pulmonary fibrosis, chronic interstitial pneumonia, chronic bronchitis, chronic sinopulmonary infection, diffuse panbronchiolitis, bronchiectasis, asthma, pancreatitis, nephritis, hepatic failure, chronic rheumatoid arthritis, joint scleroma, osteoarthritis, psoriasis, periodontitis, atherosclerosis, rejection against organ transplant, premature amniorrhexis, bullous dermatosis, shock, sepsis, systemic lupus erythematosus (SLE),

Crohn's disease, disseminated intracapillary coagulation (DIC), tissue injury after ischemia/reperfusion, formation of corneal cicatricial tissue, and myelitis.

In the specification, data is presented which shows that the claimed compounds can inhibit elastase *in vitro*. The examiner will stipulate that inhibition of elastase will occur *in vivo* as well. In addition to the foregoing, an experiment is described (page 23) in which one of the claimed compounds is administered to hamsters, followed by administration of neutrophil elastase; the concentration of hemoglobin in the washing of the broncho-alveolar lavage was subsequently measured. It was found that the amount of hemoglobin in the washing of the broncho-alveolar lavage was reduced if the (claimed) compound was administered, relative to the amount of hemoglobin present if the compound was not administered. Based on these results, it is asserted (in effect) that one or more of the diseases referred to above can be successfully treated. However, it is not clear how one can justify such an extrapolation. As stated in *Ex parte Forman* (230 USPQ 546, 1986) and *In re Wands* (8 USPQ2d 1400, Fed. Cir., 1988) the factors to consider in evaluating the need (or absence of need) for "undue experimentation" are the following: quantity of experimentation necessary, amount of direction or guidance presented, presence or absence of working examples, nature of the invention, state of the prior art, relative skill of those in that art, predictability or unpredictability of the art, and breadth of the claims. As it happens, extrapolation from the two experiments described above to the various recited diseases (emphysema, respiratory

distress syndrome, pneumonia, pulmonary fibrosis, etc.) yields “unpredictable” results. First, it is not established that these diseases are exclusively, or even primarily, dependent on elastase. Numerous other enzymes are involved, as are various reactive oxygen species. Second, even if it is true that the symptoms of one of these diseases could be mitigated by administering one of the the claimed compounds **before** the onset of symptoms, it would not follow therefrom that the diseases can be successfully treated if the compound is administered **after** the disease is firmly established, and tissue damage has become extensive. Accordingly, “undue experimentation” would be required to practice the claimed invention. It is suggested that the term “pharmaceutical” be deleted.

*

Claims 4, 9 and 10 are rejected under 35 U.S.C. §112 second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- Claim 4 recites the following:

“provided that both D2 and D3 should not simultaneously be...”

This appears to be more of an exhortation than a requirement. It is suggested that the phrase “should not” be deleted,

and replaced with just: - - are not - - .

- Claim 9 is drawn to a human neutrophilic elastase inhibitor “containing” the indicated structure. However, this renders the claim indefinite as to what is meant by “containing” the structure. There are two interpretations: (a) the claim is drawn to a composition that contains the compound of formula Ib, or (b) the claim is drawn to a single compound which is obtained by deleting a hydrogen atom or hydroxyl group from the recited structure and replacing it with something else. This would include, for example, deleting the following substituent:



and replacing it with the following: $\text{HOOC-CH}_2\text{-NH-OC-A-D-B-C=O}$

Is this intended? One option for claim language would be the following:

A composition comprising a pharmaceutically acceptable carrier and compound of the following formula

{formula as recited}

in an amount effective to inhibit human neutrophil elastase.

- Claim 10 is drawn to a composition. A composition must contain at least two components, otherwise it is just a compound. Claim 10 thus mandates the presence of a second component. It is suggested that


the second component (e.g., a pharmaceutically acceptable carrier) be recited in the claim.

*

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 703-308-3213. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached at (703) 308-2923. The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.



DAVID LUKTON
PATENT EXAMINER
GROUP 1653

DAVID LUKTON
PATENT EXAMINER
GROUP 1653

11/12/03